Our News on Newswise

Newswise: DrAhnert.jpg

NCCN Oncology Research Program Announces Projects Selected for Funding to Study Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology

The NCCN Oncology Research Program (ORP) today announced four projects selected to receive funding for clinical and pre-clinical evaluation of futibatinib (TAS-120) in collaboration with Taiho Oncology.
23-Jul-2020 8:35 AM EDT Add to Favorites

NCCN Explores Adoption of Biosimilars in Oncology in Collaboration with Pfizer

National Comprehensive Cancer Network issues Request for Proposals (RFP) for projects that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology.
15-Jul-2020 8:35 AM EDT Add to Favorites

Newswise: NCCN-DistressThermometer.jpg

Translated Tool from NCCN Measures Mental Health "Temperature" of People with Cancer

The NCCN Distress Thermometer enables discussion and treatment of distress as part of routine care for people with cancer. This free resource is now translated into 46 languages for global accessibility.
13-Jul-2020 8:00 AM EDT Add to Favorites

Newswise: JulyJNCCNcover.jpg

JNCCN Study Explores if Insurance is Keeping Pace with Trends in Targeted Cancer Therapy

New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as...
6-Jul-2020 4:15 PM EDT Add to Favorites

Newswise: PtGL-CAR_T-Cover.jpg.jpg

NCCN: What People with Cancer and their Caregivers Need to Know about CAR T-Cell Therapy

The National Comprehensive Cancer Network (NCCN) has published a new NCCN Guidelines for Patients: Immunotherapy Side Effects focused on chimeric antigen receptor (CAR) T-cell therapy. This is book two in a series that includes another book on irAEs...
30-Jun-2020 11:35 AM EDT Add to Favorites

Newswise: PtGL-ICI-Cover.jpg

How to Recognize Side-Effects from Immunotherapy? New NCCN Guidelines for Patients can Help

New NCCN Guidelines for Patients: Immunotherapy Side Effects - Immune Checkpoint Inhibitors from National Comprehensive Cancer Network and NCCN Foundation shares information for patients and caregivers on how to recognize and manage adverse events...
29-Jun-2020 8:50 AM EDT Add to Favorites

Newswise: NCCN-PedALL-Translations.jpg

NCCN Works to Improve Global Cancer Care for Children with Newly Translated Recommendations

NCCN Guidelines for Pediatric Acute Lymphoblastic Leukemia (ALL) in Chinese, Japanese, French, Spanish, and Portuguese are now available for free at NCCN.org
16-Jun-2020 8:35 AM EDT Add to Favorites

NCCN Policy Summit Explores 21st Century Cures Act and the Impact of Health Information Technology

Online summit from NCCN on 21st Century Cures Act includes bipartisan sponsors, regulatory authorities; examines the impact on and from COVID-19 on cancer care and technology; presents policy recommendations for using data to advance patient access...
10-Jun-2020 3:05 PM EDT Add to Favorites


See All News

Our Experts on Newswise

Our experts are coming soon...

Our YouTube Videos

About

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN.

Contacts

Rachel Darwin
Public Relations Manager

darwin@nccn.org

267-622-6624

Mary Ellen Martelli
Accounting Cordinator

martelli@nccn.org

267-622-6636

Erin Frantz

frantz@nccn.org

Jenn Tredwell

tredwell@nccn.org

Jessica Wilbur

wilbur@nccn.org

Twitter

close
1.62237